Gint4.T-siHDGF chimera-capped mesoporous silica nanoparticles encapsulating temozolomide for synergistic glioblastoma therapy

Huaijun Fei,Yang Jin,Nan Jiang,Yuhan Zhou,Ningcheng Wei,Yifan Liu,Jiayi Miao,Liying Zhang,Rui Li,Aixia Zhang,Shuhu Du

DOI: https://doi.org/10.1016/j.biomaterials.2024.122479

IF: 14

2024-01-22

Biomaterials

Abstract:Due to glioblastoma (GBM) being the most intractable brain tumor, the continuous improvement of effective treatment methods is indispensable. The combination of siRNA-based gene therapy and chemotherapy for GBM treatment has now manifested great promise. Herein, Gint4. T-siHDGF chimera-capped mesoporous silica nanoparticles (MSN) encapsulating chemotherapy drug temozolomide (TMZ), termed as [email protected] , is developed to co-deliver gene-drug siHDGF and TMZ for synergistic GBM therapy. [email protected] possesses spherical nucleic acid-like architecture that can improve the enzyme resistance of siHDGF and increase the blood-brain barrier (BBB) permeability of the nanovehicle. The aptamer Gint4. T of chimera endows the nanovehicle with GBM cell-specific binding ability. When administered systemically, [email protected] can traverse BBB and enter GBM cells. In the acidic lysosome environment, the cleavage of benzoic-imine bond on MSN surface leads to an initial rapid release of chimera, followed by a slow release of TMZ encapsulated in MSN. The sequential release of siHDGF and TMZ first allows siHDGF to exert its gene-silencing effect, and the downregulation of HDGF expression further enhances the cytotoxicity of TMZ. In vivo experimental results have demonstrated that [email protected] significantly inhibits tumor growth and extends the survival time of GBM-bearing mice. Thus, the as-developed [email protected] affords a potential approach for the combination treatment of GBM.

engineering, biomedical,materials science, biomaterials